Dr. Reder is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5841 S. MARYLAND AVE.
Neurology M/C 2030
Chicago, IL 60637Phone+1 773-702-6222Fax+1 773-702-9076
Summary
- Dr. Anthony Reder is a neurologist based in Chicago, IL, specializing in neuroimmunology with a focus on multiple sclerosis. He completed his medical education at the University of Michigan Medical School and a neurology residency at the University of Minnesota. His expertise extends to general neurology, neuroimmunology, multiple sclerosis, optic neuritis, and neuroimaging. Dr. Reder has published multiple articles on multiple sclerosis and its immune abnromalities, contributing to journals such as Annals of Neurology, Journal of Interferon & Cytokine Research, and Journal of Neuroimmunology. He has been involved in clinical trials examining treatments for multiple sclerosis, including studies on interferon-beta, fingolimod, ocrelizumab, glatiramer plus estriol. Recognized as one of America’s Top Doctors by Castle Connolly (2002-2025) and a top doctor by Chicago Magazine, Dr. Reder has received accolades for his contributions to the field.
Education & Training
University of MinnesotaResidency, Neurology, 1978 - 1982
University of Michigan Medical SchoolClass of 1978
Certifications & Licensure
IL State Medical License 1982 - 2026
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2015
- Chicago Magazine: Top Doctors Castle Connolly, 2004, 2006, 2008, 2010, 2012, 2014
Clinical Trials
- A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS) Start of enrollment: 2007 Mar 01
- Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) Start of enrollment: 2016 Dec 01
- Mechanism of Action of Ocrelizumab in Multiple Sclerosis Start of enrollment: 2017 Oct 12
Publications & Presentations
PubMed
- Cardiovascular hemodynamic response to peak exercise in individuals with multiple sclerosis.Brooks A Hibner, Natalia S Lima, Sara R Sherman, Robert W Motl, Julio A Chirinos
Physiological Reports. 2024-12-01 - Congenital absence of touch does not preclude normal cognitive and socioemotional development.Peggy Mason, Anthony Reder, Maureen Lacy, Jayant Pinto
Research Square. 2024-08-07 - 3 citationsAlternative Splicing of RNA Is Excessive in Multiple Sclerosis and Not Linked to Gene Expression Levels: Dysregulation Is Corrected by IFN-β.Anthony T Reder, Aika Goel, Tzintzuni Garcia, Xuan Feng
Journal of Interferon & Cytokine Research. 2024-08-01
Press Mentions
Darren P. Baker, PhD a Pioneer in the Development of Pegylated Interferon-Β for Clinical UseMarch 1st, 2023
New Study Shows Extent That Interferon Affects Activity of Immune Genes in People with MSNovember 7th, 2019
New Multiple Sclerosis Treatment Offers Breakthrough for PatientsApril 20th, 2017- Join now to see all
Research History
- NMSS Sylvia Lawry and NIH FellowMentor, Jack Antel1982 - 1984
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
